Q3 2025 saw improved operating and net results despite lower revenue, with equity restored through a rights issue and ongoing partner discussions for S1053. The company is positioned for potential breakthroughs in brain tumor treatment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.